Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
British Journal of Haematology|November 16, 2012
Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopRoger G Owen, Robert A Kyle, Marvin J Stone, et al.
Blood|March 2, 2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugsCandida Vitale, Chiara Salvetti, Valentina Griggio, et al.
Blood Advances|September 15, 2021
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?Alessandra Tedeschi, Anna Maria Frustaci, Francesca Romana Mauro, et al.
Cancers|July 2, 2021
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibFrancesca Romana Mauro, Diana Giannarelli, Andrea Visentin, et al.
Leukemia|November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's MacroglobulinemiaIrene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Blood|January 15, 2005
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocolMarco Mancini, Daniela Scappaticci, Giuseppe Cimino, et al.
Therapeutic Advances in Hematology|October 17, 2022
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemiaAnna Maria Frustaci, Giovanni Del Poeta, Andrea Visentin, et al.
Pageof 17